Express Scripts (ESRX)
ESRX (NASDAQ:Health Services)
$63.08
+0.14
+0.23%
Today's Range: 62.66 - 63.20 |
ESRX Avg Daily Volume: 4,928,700
| Last Update: 06/19/13 - 1:46 PM EDT |
| Volume: 1,272,094 |
| YTD Performance: 16.56%
|
| Open: $63.06 |
| Previous Close: $62.94 |
| 52 Week Range: $49.79 -
$66.06 |
| Oustanding Shares: 817,529,000 |
| Market Cap: 51,487,976,420 |
6-Month Chart
TheStreet Ratings Grade for ESRX
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
11 |
10 |
9 |
11 |
| Moderate Buy |
3 |
3 |
3 |
3 |
| Hold |
3 |
2 |
3 |
4 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.50 |
1.43 |
1.57 |
1.58 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
06/27/05 |
| Price Earnings Ratio: |
37.27 |
|
| Price Earnings Comparisons: |
| ESRX |
Sector Avg. |
S&P 500 |
| 37.27 |
36.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
6.34%
|
17.01%
|
20.99%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
103.50 |
2.79 |
0.55 |
| Net Income |
4.30 |
0.64 |
0.18 |
| EPS |
-30.80 |
0.15 |
0.05 |
| Earnings for ESRX: |
| EBITDA |
4.66B |
| Revenue |
93.86B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.10 |
$1.09 |
$4.29 |
$4.94 |
| Number of Analysts |
13 |
12 |
14 |
14 |
| High Estimate |
$1.13 |
$1.11 |
$4.32 |
$5.15 |
| Low Estimate |
$1.09 |
$1.07 |
$4.23 |
$4.75 |
| Prior Year |
$0.88 |
$1.02 |
$3.74 |
$4.29 |
| Growth Rate (Year over Year) |
25.35% |
6.70% |
14.80% |
14.94% |
| Jun 18, 2013 | 10:30 AM EDT
Which figures should you use to make investment decisions?
| May 13, 2013 | 9:07 AM EDT
A normally reliable short-term indicator looks bearish.
May 13, 2013 | 7:59 AM EDT
ESRX was upgraded from Hold to Buy, Jefferies said. $74 price target. Uncertainty is gone and the company should resume share repurchas...
May 01, 2013 | 8:06 AM EDT
ESRX estimates were raised through 2014, BMO Capital said. Company continues to execute on its plan. Market Perform rating and new $62 ...
| Apr 22, 2013 | 1:49 PM EDT
Express Scripts and McKesson could both see weakness.
| Mar 14, 2013 | 11:30 AM EDT
For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.
Feb 28, 2013 | 8:17 AM EST
ESRX estimates were boosted through 2014, Citigroup said. Company is keeping a tight lid on costs. Buy rating and new $64 price target....
| Feb 25, 2013 | 2:10 PM EST
These two solid names are finding support at their longer-term moving averages.
Feb 20, 2013 | 7:57 AM EST
Shares of ESRX now seen reaching $65, according to Lazard Capital Markets. Estimates also upped, given better operating trends. Buy rat...
| Feb 01, 2013 | 10:00 AM EST
It’s much tougher to actually “buy low to sell high” than it is to espouse the concept.
